这个药不错，３年前的临床结果非常好，估计ＦＤＡ会批

Preliminary results from a small clinical trial of a new drug, Cabozantinib

(XL184) have shown unprecedented response rates: Bone metastases

improved in 85% of patients with castration-resistant prostate cancer

(CRPC) who completed the 12 week lead-in period. Another 13% had

stable disease resulting in an overall rate of bone disease control of

98%. Of 43 evaluable patients with bone pain, 26 (60%) had measurable

improvement with reduced pain as early as six weeks after starting

cabozantinib.